Elevai Labs files two patent applications for EL-22 in muscle loss

Elevai Labs filed two novel patent applications for its lead candidate, EL-22, aimed at treating muscle loss in obese patients. These patent applications cover both standalone and combination therapies using EL-22 alongside GLP-1 receptor agonists, marking a significant advancement in obesity treatment. The newly filed patent applications support the development of EL-22, an engineered probiotic expressing myostatin, designed to revolutionize obesity care by preserving muscle mass while reducing fat mass. EL-22 has successfully completed a Phase 1 clinical trial in South Korea, demonstrating safety and tolerability in healthy volunteers. Elevai now plans to assess the efficacy of EL-22 in combination with leading weight-loss therapies to address muscle wasting-a common side effect of GLP-1 medications-while promoting fat loss. Elevai Biosciences’ patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets, including the USA, Japan, China and Korea.